Virtu Financial LLC Takes $486,000 Position in Immunome, Inc. (NASDAQ:IMNM)

Virtu Financial LLC acquired a new position in Immunome, Inc. (NASDAQ:IMNM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 45,743 shares of the company's stock, valued at approximately $486,000. Virtu Financial LLC owned approximately 0.06% of Immunome as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. FMR LLC raised its holdings in shares of Immunome by 0.3% during the third quarter. FMR LLC now owns 4,224,700 shares of the company's stock valued at $61,765,000 after acquiring an additional 13,757 shares during the period. Janus Henderson Group PLC raised its stake in Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company's stock valued at $50,971,000 after purchasing an additional 324,614 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Immunome by 13.6% in the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company's stock valued at $17,657,000 after purchasing an additional 144,557 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Immunome by 22.2% in the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company's stock worth $6,881,000 after buying an additional 85,580 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Immunome by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company's stock valued at $4,856,000 after buying an additional 14,775 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.

Remove Ads

Insider Activity at Immunome

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the business's stock in a transaction on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the transaction, the chief executive officer now directly owns 669,636 shares of the company's stock, valued at $5,189,679. This represents a 28.87 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CTO Philip Tsai acquired 12,300 shares of the company's stock in a transaction dated Monday, March 24th. The shares were bought at an average price of $8.42 per share, for a total transaction of $103,566.00. Following the purchase, the chief technology officer now owns 33,300 shares in the company, valued at approximately $280,386. This represents a 58.57 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 306,400 shares of company stock valued at $2,322,995. 8.60% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Lifesci Capital initiated coverage on Immunome in a research note on Tuesday, March 11th. They set an "outperform" rating and a $20.00 target price on the stock. Wedbush reiterated an "outperform" rating and issued a $33.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Guggenheim decreased their target price on shares of Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, March 20th. Finally, Stephens restated an "overweight" rating and set a $30.00 price target on shares of Immunome in a report on Thursday, March 20th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $25.50.

Immunome Stock Down 4.0 %

IMNM stock traded down $0.29 during midday trading on Friday, reaching $6.99. The company's stock had a trading volume of 1,060,189 shares, compared to its average volume of 854,933. The business's 50-day simple moving average is $9.50 and its 200-day simple moving average is $11.31. Immunome, Inc. has a 52 week low of $6.90 and a 52 week high of $24.87. The stock has a market cap of $607.79 million, a PE ratio of -0.86 and a beta of 1.93.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The firm had revenue of $2.74 million during the quarter, compared to analyst estimates of $3.07 million. As a group, equities analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.